Phase I study of vorinostat in combination with temozolomide in patients with malignant gliomas.
P. Y. Wen
Research Funding - Merck
V. K. Puduvalli
No relevant relationships to disclose
J. G. Kuhn
No relevant relationships to disclose
J. M. Reid
No relevant relationships to disclose
K. Lamborn
No relevant relationships to disclose
T. F. Cloughesy
No relevant relationships to disclose
S. M. Chang
No relevant relationships to disclose
J. Drappatz
No relevant relationships to disclose
W. K. A. Yung
No relevant relationships to disclose
M. R. Gilbert
Consultant or Advisory Role - Genentech; Sigma-Tau
Honoraria - Genentech; Merck; Sigma-Tau
Research Funding - Genentech; Merck
H. I. Robins
No relevant relationships to disclose
F. S. Lieberman
No relevant relationships to disclose
A. B. Lassman
No relevant relationships to disclose
R. M. McGovern
No relevant relationships to disclose
S. Desideri
No relevant relationships to disclose
X. Ye
No relevant relationships to disclose
M. M. Ames
No relevant relationships to disclose
I. J. Espinoza-Delgado
No relevant relationships to disclose
S. A. Grossman
No relevant relationships to disclose
M. Prados
No relevant relationships to disclose